Clinical Impact of Extranodal Metabolic Tumor Volume in 240 Diffuse Large B cell Lymphoma Patients with Extranodal Involvement

• Published in: Annals of hematology Vol. 100; no. 5; pp. 1221 - 1229
• Main Authors: Song, Moo-Kon, Chung, Joo-Seop, Lim, Sung-Nam, Lee, Won-Sik, Lee, Sang-Min, Kim, Seong-Jang, Shim, Hye-Kyung, Lee, Seok-Mo
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.05.2021; Springer Nature B.V
• Subjects: Adult; Aged; Extranodal Extension - diagnostic imaging; Female; Hematology; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse - diagnostic imaging; Lymphoma, Large B-Cell, Diffuse - metabolism; Lymphoma, Large B-Cell, Diffuse - pathology; Male; Medicine; Medicine & Public Health; Metabolism; Middle Aged; Oncology; Original Article; Positron-Emission Tomography; Prognosis; Retrospective Studies; Survival Analysis; Tomography; Tumor Burden; Extranodal involvement; Metabolic tumor volume; Positron emission tomography
• ISSN: 0939-5555; 1432-0584
• DOI: 10.1007/s00277-021-04498-9

The present study is to investigate whether extranodal (EN) metabolic tumor volume (MTV) would have a specific clinical meaning for survival in EN diffuse large B cell lymphoma (DLBCL) patients. Two hundred forty DLBCL patients with EN involvement received 18F-fluorodeoxygenase (FDG) positron emission tomography/computed tomography (PET/CT) were enrolled. Survival analysis revealed that low EN MTV (PFS [progression-free survival], HR = 0.278, 95% CI = 0.127–0.807, p = 0.001; OS [overall survival], HR = 0.320, 95% CI = 0.145–0.703, p = 0.003), low total MTV (PFS, HR = 0.194, 95% CI = 0.085–0.445, p < 0.001; OS, HR = 0.213, 95% CI = 0.092–0.491, p < 0.007), and high National Cancer Center Network-International Prognostic Index score (PFS, HR = 3.152, 95% CI = 1.732–5.734, p < 0.001; OS, HR = 2.457, 95% CI = 1.363–4.430, p = 0.003) were independently associated with survivals in the patients. Our data showed that EN MTV is a useful and novel prognostic parameter for predicting survival in DLBCL patients with EN involvement.